rovadicitinib   Click here for help

GtoPdb Ligand ID: 12384

Synonyms: Anxu® (China) | example 5 [US10561657B2] | TQ-05105 | TQ05105
Approved drug Immunopharmacology Ligand
rovadicitinib is an approved drug
Compound class: Synthetic organic
Comment: This is the chemical structure for the INN rovadicitinib. The structure is claimed in patent US10561657B2, as a Janus kinase (JAK) inhibitor [4]. It later transpired that rovadicitinib (TQ05105) was a dual JAK1/2 and Rho kinase (ROCK) 1/2 inhibitor [5].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 109.2
Molecular weight 321.17
XLogP 2.2
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES N#CC[C@@H](n1nc(c(c1)c1ncnc2c1cc[nH]2)N)C1CCCC1
Isomeric SMILES C1CCC(C1)[C@@H](CC#N)n1cc(c(n1)N)c1c2cc[nH]c2ncn1
InChI InChI=1S/C17H19N7/c18-7-5-14(11-3-1-2-4-11)24-9-13(16(19)23-24)15-12-6-8-20-17(12)22-10-21-15/h6,8-11,14H,1-5H2,(H2,19,23)(H,20,21,22)/t14-/m1/s1
InChI Key ZGENDZDSLYKCSI-CQSZACIVSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Rovadicitinib was progressed as a clinical candidate for the treatment of the inflammatory and fibrotic components of myelofibrotic conditions [3], and chronic graft-versus-host disease (cGVHD) [5]. It was first approved in China in early 2026, to treat primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04339400 A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms Phase 1 Interventional Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT05020652 A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis Phase 2 Interventional Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT06300320 A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease Phase 2 Interventional Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT04944043 A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease Phase 1/Phase 2 Interventional Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 5
NCT06388759 TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients Phase 1 Interventional Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 2